Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00478387 · ClinicalTrials.gov registry record
Ovarian Cancer and Immune Response to Flu Vaccine
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 37
- Enrollment target
NCT00478387: Completed study, sponsored by University of Pennsylvania.
NCT00478387 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00478387 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to determine what the immune response is of ovarian cancer patients in remission, when they are given the flu vaccine. After receiving the flu vaccine, patients will have blood drawn 5 times in 12 months to study antibody response to the flu vaccine.
Interventions
- BIOLOGICAL The current season's trivalent killed influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2006-10 |
| Est. Completion | 2011-06 |
What the finished NCT00478387 record still lists
NCT00478387 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which The current season's trivalent killed influenza vaccine is the first listed.
NCT00478387 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00478387 about?
NCT00478387 is a clinical study titled "Ovarian Cancer and Immune Response to Flu Vaccine". The purpose of this study is to determine what the immune response is of ovarian cancer patients in remission, when they are given the flu vaccine. After receiving the flu vaccine, patients will have blood drawn 5 times in 12 months to study antibody response to the flu vaccine.
What is the current status of trial NCT00478387?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2006-10. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00478387?
The interventions under investigation include: The current season's trivalent killed influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00478387?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia